Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) Files An 8-K Shareholder Director NominationsItem 5.08 Shareholder Director Nominations.
Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) Files An 8-K Shareholder Director Nominations
On November 22, 2016, Rexahn Pharmaceuticals, Inc. (the “Company”) set the date of the 2017 Annual Meeting of Stockholders of the Company (the “2017 Annual Meeting”) as April 11, 2017.
Any stockholder proposal intended for inclusion in the Company’s proxy materials for the 2017 Annual Meeting must be received by the Company at its offices at 15245 Shady Grove Road, Suite 455, Rockville, Maryland 20850 no later than December 19, 2016.
Any stockholder intending to present a proposal at the 2017 Annual Meeting without it being included in the Company’s proxy materials must comply with the advance notice provisions of the Company’s Amended and Restated Bylaws. to these provisions, the Company must receive the proposal at its offices not earlier than the close of business on December 12, 2016 and not later than the close of business on January 11, 2017 in order to be brought before the 2017 Annual Meeting.
About Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN)
Rexahn Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development and commercialization of treatments for cancer. The Company’s clinical-stage drug candidates in active development include Archexin, RX-3117 and Supinoxin (RX-5902). Archexin is a potent inhibitor of the protein kinase Akt-1, which focuses on cancer cell proliferation, survival, angiogenesis, metastasis and drug resistance. RX-3117 is a small molecule nucleoside compound with an anti-metabolite mechanism of action and has therapeutic potential in a range of cancers, including pancreatic, bladder, colon and lung cancer. Supinoxin is a small molecule inhibitor of phosphorylation of p68. The Company also has a drug candidate RX-21101, an N-(2-Hydroxypropyl) methacrylamide-docetaxel-folate, in pre-clinical development. The Company is working on research technologies, including multi-target aimed ligands platform and nano-based drug delivery systems. Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) Recent Trading Information
Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) closed its last trading session down -0.008 at 0.171 with 588,749 shares trading hands.
Rexahn Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development and commercialization of treatments for cancer. The Company’s clinical-stage drug candidates in active development include Archexin, RX-3117 and Supinoxin (RX-5902). Archexin is a potent inhibitor of the protein kinase Akt-1, which focuses on cancer cell proliferation, survival, angiogenesis, metastasis and drug resistance. RX-3117 is a small molecule nucleoside compound with an anti-metabolite mechanism of action and has therapeutic potential in a range of cancers, including pancreatic, bladder, colon and lung cancer. Supinoxin is a small molecule inhibitor of phosphorylation of p68. The Company also has a drug candidate RX-21101, an N-(2-Hydroxypropyl) methacrylamide-docetaxel-folate, in pre-clinical development. The Company is working on research technologies, including multi-target aimed ligands platform and nano-based drug delivery systems. Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) Recent Trading Information
Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) closed its last trading session down -0.008 at 0.171 with 588,749 shares trading hands.
